1,360 results on '"Simonneau G"'
Search Results
2. Nouvelles définitions et classification de l’hypertension pulmonaire
3. Traitement chirurgical de l’hypertension pulmonaire thromboembolique
4. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
5. Klippel-Trenaunay syndrome as a rare cause of chronic thromboemboembolic pulmonary hypertension
6. La maladie veino-occlusive pulmonaire
7. Medical bridging therapy before pulmonary endarterectomy?
8. External Validation of a Refined 4 Strata Risk Assessment Score from the French Pulmonary Hypertension Registry
9. Доклад ERS по хронической тромбоэмболической легочной гипертензии
10. ERS statement on chronic thromboembolic pulmonary hypertension
11. Changes in cMRI parameters following a switch to riociguat from phosphodiesterase type 5 inhibitors (PDE5i) in patients with pulmonary arterial hypertension: a REPLACE substudy
12. Treatment effect of selexipag on time to disease progression when initiated early in pulmonary arterial hypertension (PAH) patients: GRIPHON and TRITON pooled analysis
13. BIOMARKERS IN THE RESPITE TRIAL INVESTIGATING RIOCIGUAT IN PAH PATIENTS WITH INSUFFICIENT RESPONSE TO PDE-5I: 113
14. Les voies de recherche
15. Traitement anticoagulant de l’embolie pulmonaire : Quel traitement ? Quelle durée ?
16. Nouvelle classification de l’HTAP
17. Physiopathologie de l’hypertension artérielle pulmonaire
18. Approches thérapeutiques actuelles dans l’HTAP
19. Embolia polmonare cronica
20. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry
21. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry
22. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial
23. Switching to Riociguat from Phosphodiesterase-5 Inhibitors, With or Without Endothelin Receptor Antagonists, in Patients with Pulmonary Arterial Hypertension: Results from the REPLACE Study
24. BPA and Riociguat for the Management of Inoperable CTEPH: Results of the Extension Study Following the RACE Randomized Controlled Trial (RCT)
25. Screening for Pulmonary Arterial Hypertension in Adults Carrying a BMPR2 Mutation
26. Initial Triple Oral Therapy in Pulmonary Arterial Hypertension (PAH): Extended Long-Term Outcome Data from TRITON
27. Analysis of Risk Assessment Tools in the REPLACE Study
28. Diagnostic et prise en charge de l’hypertension pulmonaire postembolique : le rôle du pneumologue
29. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial
30. S94 Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
31. Trithérapie initiale dans l’hypertension artérielle pulmonaire
32. Prise en charge diagnostique et thérapeutique de l'hypertension artérielle pulmonaire
33. Prueba de marcha de seis minutos en neumología
34. Il test del cammino per sei minuti in pneumologia
35. Traitement médical de l'hypertension artérielle pulmonaire
36. Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: insights from the randomised controlled TRITON study
37. Pulmonary hypertension in orphan lung diseases
38. A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer
39. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension
40. Computed tomography findings of pulmonary venoocclusive disease in scleroderma patients presenting with precapillary pulmonary hypertension
41. S.4.1 N-terminal pro-brain natriuretic peptide levels predict incident pulmonary arterial hypertension in SSc
42. Chronic thromboembolic and pulmonary arterial hypertension share right ventricular and pulmonary artery CMR features
43. Current management approaches to portopulmonary hypertension
44. Efficacy and Safety of Initial Triple Oral Versus Initial Double Oral Combination Therapy in Patients with Newly Diagnosed Pulmonary Arterial Hypertension (PAH): Results of the Randomized Controlled TRITON Study
45. Safety of Riociguat for the Treatment of Pulmonary Arterial Hypertension Associated with Connective Tissue Disease: Data from the EXPERT Registry
46. Safety of Riociguat in Patients Receiving Concomitant Prostanoids: Data from the EXPERT Registry
47. Safety of Riociguat in Patients with Inoperable CTEPH and Persistent/Recurrent CTEPH: Data from the EXPERT Registry
48. Safety of Riociguat in Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension with Concomitant Novel Oral Anticoagulants or Vitamin K Antagonist Use: Data from the EXPERT Registry
49. Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities
50. The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.